ESMO Congress 2025

 

Review videos and news releases from Dana-Farber physician-scientists at the ESMO Congress 2025.

FLAURA2 Lung Cancer Study Presented by Pasi Jänne, MD, PhD Video

FLAURA2 Lung Cancer Study Presented by Pasi Jänne, MD, PhD

Dana-Farber Cancer Institute's Dr. Pasi Jänne details FLAURA2 which found first-line osimertinib + platinum pemetrexed chemotherapy improved overall survival vs. monotherapy in EGFR mutated non-small cell lung cancer, including poorer prognosis patients.
Pasi A. Jänne, MD, PhD

Pasi A. Jänne, MD, PhD

Medical Oncology
KIM-1 in Kidney Cancer Study Presented by Vincent Xu, MD Video

KIM-1 in Kidney Cancer Study Presented by Vincent Xu, MD

Dana-Farber Cancer Institute's D. Wenxin (Vincent) Xu shares research suggesting a blood test measuring levels of the KIM-1 biomarker could help assess the burden of disease in advanced kidney cancer and predict outcomes during first-line treatment.
Wenxin Xu, MD

Wenxin Xu, MD

Medical Oncology
ASCENT-03 Study Presented by Sara Tolaney, MD, MPH Video

ASCENT-03 Study Presented by Sara Tolaney, MD, MPH

Dr. Sara Tolaney details research in The New England Journal of Medicine showing the ADC sacituzumab govitecan improved outcomes for patients with advanced triple-negative #BreastCancer ineligible for immune checkpoint inhibitors.
Sara M. Tolaney, MD, MPH

Sara M. Tolaney, MD, MPH

Medical Oncology
Head and Neck Study Presented by Robert Haddad, MD  Video

Head and Neck Study Presented by Robert Haddad, MD 

Dana-Farber's Dr. Robert Haddad says research shows the combination of a PD1 with anti-LAG3 +/- anti-TIM3 does not improve outcomes in metastatic disease, raising the question of whether to look at this combo earlier, in the neoadjuvant setting.
Robert I. Haddad, MD

Robert I. Haddad, MD

Medical Oncology

News Releases

 

Featured Speakers

 

Follow us on social media